The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|January 17, 2022
Next steps to advancing metastatic kidney cancer care
Author(s)Urology Times staff
Advertisement
Sarah Elizabeth Yentz, MD, clinical assistant professor, University of Michigan Health, medical oncologist, Brighton Center for Specialty Care, Rogel Cancer Center, Michigan Medicine, explains what sequencing research and novel treatment development is needed in metastatic renal cell carcinoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5